Orchestra BioMed Holdings (OBIO) Assets Average (2021 - 2026)
Orchestra BioMed Holdings (OBIO) posted quarterly Assets Average of $107.8 million for Q1 2026, up 59.38% year-over-year from $67.6 million in Q1 2025, and down 1.89% quarter-over-quarter from $109.8 million in Q4 2025.
Orchestra BioMed Holdings (OBIO) Assets Average (2021 - 2026) Analysis & Trends
Orchestra BioMed Holdings (OBIO) has reported Assets Average for 6 consecutive years, with $107.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average rose 59.38% year-over-year to $107.8 million; the TTM figure through Mar 2026 stood at $107.8 million (up 59.38% YoY), while the FY2025 annual figure was $95.5 million, up 11.46% from the prior year.
- Assets Average declined to $107.8 million in Q1 2026 per OBIO's latest filing, from $109.8 million in the prior quarter.
- Across five years, Assets Average topped out at $161.7 million in Q1 2022 and bottomed at $50.9 million in Q2 2025.
- Historically, Assets Average has averaged $101.2 million across 5 years, with a median of $105.8 million in 2023.
- Annual changes were most pronounced in 2022 — Assets Average plunged 49.27% — and 2026, when it soared 59.38%.
- Orchestra BioMed Holdings' Assets Average stood at $82.1 million in 2022, then gained by 28.83% to $105.8 million in 2023, then fell by 28.4% to $75.7 million in 2024, then surged by 45.0% to $109.8 million in 2025, then slipped by 1.89% to $107.8 million in 2026.
- Business Quant data shows OBIO's Assets Average at $107.8 million in Q1 2026, $109.8 million in Q4 2025, and $73.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Orchestra BioMed Holdings | 265.06 Mn | 80.63 Mn | 63,000.00 | 108.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 108.18 Mn |
| Mar 31, 2026 | 107.76 Mn |
| Dec 31, 2025 | 109.83 Mn |
| Sep 30, 2025 | 73.82 Mn |
| Jun 30, 2025 | 50.94 Mn |
| Mar 31, 2025 | 67.61 Mn |
| Dec 31, 2024 | 75.75 Mn |
| Sep 30, 2024 | 73.85 Mn |
| Jun 30, 2024 | 77.51 Mn |
| Mar 31, 2024 | 88.92 Mn |
| Dec 31, 2023 | 105.78 Mn |
| Sep 30, 2023 | 121.12 Mn |
| Jun 30, 2023 | 131.08 Mn |
| Mar 31, 2023 | 115.93 Mn |
| Dec 31, 2022 | 82.11 Mn |
| Sep 30, 2022 | 115.12 Mn |
| Jun 30, 2022 | 161.55 Mn |
| Mar 31, 2022 | 161.68 Mn |
| Dec 31, 2021 | 161.85 Mn |
| Sep 30, 2021 | 161.96 Mn |